首页 | 本学科首页   官方微博 | 高级检索  
     

PPAR激动剂在治疗非酒精性脂肪性肝病中的应用前景
引用本文:李秀丽,王晓晖. PPAR激动剂在治疗非酒精性脂肪性肝病中的应用前景[J]. 中国医院药学杂志, 2015, 35(23): 2153-2156. DOI: 10.13286/j.cnki.chinhosppharmacyj.2015.23.22
作者姓名:李秀丽  王晓晖
作者单位:1. 赤峰学院医学院, 内蒙古赤峰 024000;2. 赤峰学院附属医院, 内蒙古赤峰 024000
基金项目:内蒙古自治区自然科学基金项目(编号:2013MS1115);内蒙古自治区高等学校科学研究项目(编号:NJZC13316);赤峰学院重点实验室建设项目资助
摘    要:由于肥胖症和2型糖尿病患者越来越多,非酒精性脂肪性肝病(NAFLD)也呈现逐年上升趋势。NAFLD可引起肝硬化和肝癌等并发症,严重威胁公众健康,目前尚无有效治疗NAFLD及其并发症的药物。肝脏甘油三酯聚集是NAFLD的重要标志,过氧化物酶体增殖物活化受体(PPAR)可参与脂代谢、糖代谢以及炎症的调控。本文综述了PPAR参与NAFLD的可能作用机制以及治疗NAFLD的PPAR激动剂的研究进展。

关 键 词:非酒精性脂肪性肝病  过氧化物酶增殖物活化受体  过氧化物酶增殖物活化受体激动剂  
收稿时间:2015-03-30

Application prospect of peroxisome proliferator-activated receptor agonists against non-alcoholic fatty liver diseases
LI Xiu-li,WANG Xiao-hui. Application prospect of peroxisome proliferator-activated receptor agonists against non-alcoholic fatty liver diseases[J]. Chinese Journal of Hospital Pharmacy, 2015, 35(23): 2153-2156. DOI: 10.13286/j.cnki.chinhosppharmacyj.2015.23.22
Authors:LI Xiu-li  WANG Xiao-hui
Affiliation:1. Medical College of Chifeng University, Inner Mongolia Chifeng 024000, China;2. Affiliated Hospital of Chifeng University, Inner Mongolia Chifeng 024000, China
Abstract:Nowadays,non-alcoholic fatty liver disease(NAFLD)is increasing with prevalence of obesity and type-2 diabetes.Therefore,NAFLD deeply influences public health.NAFLD can cause many complications,such as cirrhosis and liver cancer.At present,no effective drug has been approved for NAFLD and its complications.Peroxisome proliferator-activated receptor(PPAR),activator of nuclear receptor ligands,participates in regulation of lipid metabolism,glucose metabolism and inflammation.This review summarizes possible mechanism of PPAR participated in NAFLD and study advances in PPAR agonists against NAFLD.
Keywords:non-alcoholic fatty liver disease(NAFLD)  peroxisome proliferator-activated receptor(PPARs)  PPAR agonists  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号